Numinus has shared an update on its MDMA-assisted therapy for PTSD trial, which is being pursued in collaboration with MAPS Public Benefit Corp. Following the successful completion of a number of milestones – including the recruitment of therapists, physicians, and staff – the trial has advanced to the pre-implementation stage at the company’s Vancouver clinic. Initial meetings with Health Canada…


Previous articleLobe Sciences Successfully Completes Proof-of-Concept of Proprietary Nasal Mist Device
Next articleThe Veterans’ Experience: Psychedelic Treatments for PTSD